Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

Clinical trial NCT07224776 · RECRUITING

Trial details

NCT number: NCT07224776
Sponsor: Brigham and Women's Hospital
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Proteinuric Renal Disease Proteinuric Kidney Disease Proteinuria Proteinuria in Nephrotic Range

Start date: 2026-07-10
Primary completion: 2026-12-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.